// App-Quantinova.ai

342 : A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk

Researchers

Presenter

  • Toni Choueiri

Principal Investigators

  • Laurence Albiges

  • Thomas Powles

  • Nehal Mohamed

  • Fong Wang

  • Robert Motzer

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Institut Gustave Roussy, Villejuif, Ile-de-France, France

  • Barts Cancer Institute, QMUL, London, UK

  • Exelixis, Alameda, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Cabozantinib

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved